CASP3 and neoplasm: BACA has large CNA deletions of the lung adenocarcinoma tumor suppressor PIK3R1 (<1% of human cases) [36] and the pan cancer tumor suppressor CASP3. CLAC has a large CNA gain including NRAS, a known lung adenocarcinoma driver in 0.4% of human cases [36].